3,4-Methylenedioxy-N-propargylamphetamine

MDPL
Clinical data
Other namesMDPL
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]prop-2-yn-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H15NO2
Molar mass217.268 g·mol−1
3D model (JSmol)
  • CC(NCC#C)Cc1ccc2OCOc2c1
  • InChI=1S/C13H15NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h1,4-5,8,10,14H,6-7,9H2,2H3
  • Key:LRYUTPIBTLEDJJ-UHFFFAOYSA-N

3,4-Methylenedioxy-N-propargylamphetamine (MDPL) is a lesser-known drug and a substituted amphetamine.[1] MDPL was first synthesized by Alexander Shulgin.[1] In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown.[1] MDPL causes few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPL.[1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ a b c d e f g Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. MDPL entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.